Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
No immediate change to Ang II receptor blocker use; extends mechanistic models but leaves clinical translation open.
Angiotensin (Ang) II exerts its important physiological functions through 2 distinct receptor subtypes, type 1 (AT(1)) and type 2 (AT(2)) receptors. Recently, new evidence has accumulated showing the existence of several novel receptor interacting proteins and various angiotensin II receptor activation mechanisms beyond the classical actions of receptors for Ang II. These associated proteins could contribute not only to Ang II receptors' functions, but also to influencing pathophysiological states. Receptor dimerization of Ang II receptors such as homodimer, heterodimer, and complex formation with other G protein-coupled receptors has also been focused on as a new mechanism of their activation or inactivation. Moreover, ligand-independent receptor activation systems such as mechanical stretch for the AT(1) receptor have also been revealed. These emerging concepts of regulation of Ang II receptors and a new insight into future drug discovery are discussed in this review.
No takes yet. Share an insight, caveat, or question.
Mogi et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: